Compare FNKO & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNKO | BDSX |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.3M | 276.2M |
| IPO Year | 2017 | 2020 |
| Metric | FNKO | BDSX |
|---|---|---|
| Price | $5.34 | $27.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $6.00 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 999.8K | 116.4K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $908,209,000.00 | $88,499,000.00 |
| Revenue This Year | $4.42 | $25.26 |
| Revenue Next Year | $6.50 | $19.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $2.72 | $5.26 |
| 52 Week High | $7.35 | $31.31 |
| Indicator | FNKO | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 56.79 |
| Support Level | $5.11 | $19.26 |
| Resistance Level | $5.87 | $31.31 |
| Average True Range (ATR) | 0.35 | 2.10 |
| MACD | -0.13 | -0.15 |
| Stochastic Oscillator | 7.51 | 45.99 |
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.